Osmind

09/03/2026

“Interventional psychiatry” has been part of the field’s vocabulary for years, but there has never been a formal definition of what it really means.

Our new paper published in Nature Mental Health, “Defining interventional psychiatry: A framework for professional identity and practice evolution,” offers a clear framework for what the field is, what distinguishes it, and how it should evolve.

Nine leaders spanning clinical practice, research, academia, and industry came together to develop it: William Sauvé, MD, Thomas Insel MD, Brittany Albright MD, MPH, DABOM, Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS, Rob Berman, Stephen M. Stahl, MD, PhD, DSc(Hon), DMedSci (Hon, Cambridge), Husseini Manji, MD, FRCPC, Roger McIntyre, and Jimmy Qian.

Their central argument is simple: interventional psychiatry is not defined by a list of tools or procedures. It is defined by the integration of psychiatric judgment with the direct delivery or oversight of specialized treatments, including responsibility for patient selection, real-time management, and longitudinal care.

The paper also proposes a risk-based framework for training and credentialing, with standards matched to procedural complexity and safety rather than a one-size-fits-all certification model.

Osmind is proud to support more than 1,000 interventional psychiatry practices nationwide. A clearer definition can help establish the field’s boundaries, strengthen its professional identity, and guide the next chapter of training, practice, and patient care.

08/26/2026

"More is better" might be the most expensive reflex in interventional psychiatry.
More TMS pulses. More frequent ketamine. Higher doses for the sickest patients. On the latest Psychiatry Tomorrow episode, Lisa Harding, MD makes the case that almost none of it is backed by data, and some of it makes patients worse.

Harding trained as chief resident of interventional psychiatry at Yale, then left to build an insurance-based practice that takes TMS, Spravato, and ketamine to her community instead of reserving them for the top two percent of illness. William Sauvé, MD and Brittany Albright MD, MPH, DABOM sat down with her to get into these topics:

•Why interventional care gets reserved for the sickest patients – and why that logic is backwards

•How setting changes outcomes (including the TMS room with the creaking Frankenstein door)

•Inside the EQUIVALENCE trial, the first well-powered head-to-head of IV ketamine vs. esketamine, now enrolling ~400 patients across six sites

•Why interventional practices fail on economics long before they fail on medicine

"I do not assume safety in the absence of data."

Find it on your podcast player or at the link below.

Dr. Lisa Harding trained as Yale's chief resident in interventional psychiatry, then built an insurance-based practice to prove the treatments could reach beyond the sickest two percent. She argues TMS and ketamine work fine – what fails is the dosing logic, the treatment room, and the economics o...

08/24/2026

Registration link: https://osmind-org.zoom.us/webinar/register/2717860405904/WN_z0oeHg5GR3S4Kl22eRfRug

Tomorrow at 10:00 a.m. PT / 1:00 p.m. ET:

What Breaks When Interventional Psychiatry Practices Scale

Join Osmind host and moderator Will Sauvé, MD, along with Rise4 co-founders Jake Buchanan and Justin Gammill, for a practical conversation about finding and fixing the bottlenecks in the patient journey before adding more demand or capacity.

Register to attend live or receive the recording:

https://osmind-org.zoom.us/webinar/register/2017859740060/WN_z0oeHg5GR3S4Kl22eRfRug

08/19/2026

Join us for Q’s with Koo, a live event hosted by Dr. Martha Koo and members of the Psychiatry Collective as we explore what’s new in interventional psychiatry, from practice tips to clinical considerations.

🗓️When: Thursday, Aug 27, 11:00 AM - 11:30 AM PDT / 2 - 2:30 PM ET

No slides, no lectures; just casual chats with fellow clinicians and a cup of coffee!

Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS brings a wealth of experience as past president of the Clinical TMS Society and a leading voice in interventional psychiatry research.

She'll kick things off with a topic, but the floor is open—bring your questions on anything interventional: TMS, Spravato, psychedelics, research updates, optimizing your practice, or whatever's on your mind.

RSVP to join us live or drop your Qs in the comments and we'll cover them during the chat.

Links to register in comments!

08/18/2026

Before you add another provider, machine, or location, answer one question:

Can you see where patients are falling through the cracks?

More inquiries don't tell you whether patients are getting timely follow-up. A full schedule doesn't tell you whether every patient who reached out actually started treatment. Growth doesn't fix that. It just runs more patients through the same gaps.

The patient journey needs to be visible from that very first inquiry through intake, evaluation, treatment, and completion.

On August 25, join Will Sauvé, MD, Chief Medical Officer at Osmind, for a practical webinar featuring Rise4 co-founders Jake Buchanan and Justin Gammill. We'll show how to map the patient journey, identify where patients are being lost, and determine what to strengthen before growth adds more pressure.

Tuesday, August 25 at 10:00 a.m. PT / 1:00 p.m. ET

08/14/2026

200 miles from the nearest major city, Cassandra Heuer opened her psychiatry practice, Elevate Wellness & Psychiatry in her hometown of 14,000 people.

What started as Heuer working two to three days a week has become a multi-provider practice. Since transitioning to Osmind 360, Elevate Psychiatry's monthly appointment volume has grown by more than 220%

She brought on a medical assistant, then a second PRN provider, and once Elevate added a TMS machine, an office manager dedicated to prior authorizations, billing, and insurance. Onboarding that growing team, she says, was never the bottleneck.

"I always described it like Apple – everything is just very intuitive. You just click and can figure it out yourself. Things just make sense where they're at."

That ease mattered most for her second provider, who came from a corrections facility with no electronic prescribing or portal messaging at all.

"For her, it was incredible to transition to this newer EHR – she just caught on. I don't even know if we really did much training."

What made it possible was the clinical vision and building infrastructure that could handle the administrative weight – billing, claims, prior auths – so Cassi could focus on the patients.

08/12/2026

Osmind is partnering with Tasman Therapeutics to accelerate the development and commercialization of innovative treatments for neuropsychiatric disorders.

Osmind is leveraging our technology, real-world evidence platform, and clinical network to support Tasman's late-stage R-107 extended-release ketamine tablet program for treatment-resistant depression.

As Tasman’s technology innovation partner, our work is supporting and accelerating phase 3 ex*****on as well as spearheading a unique approach to commercial development and launch driven by data, AI, and technology.

08/10/2026

Scale doesn’t ‘fix’ a clinic’s growth system; It multiplies whatever’s already working or broken. For interventional psychiatry practices, growth puts more pressure on every handoff between patient interest and completed treatment.

More demand can expose weak intake. More capacity can magnify poor visibility. A new provider or location can make inconsistent workflows harder to manage.

Join us as we welcome Rise4 co-founders, Jake Buchanan and Justin Gammill for an Osmind webinar on August 25!

We’ll cover:
-Why more leads often expose weak intake rather than create growth
-What dedicated, optimized intake ownership does differently
-How to track conversion beyond the lead and identify where patients fall out
-How to assess whether your clinic is ready for more demand or capacity

Be sure to catch the live Q&A at the end of this webinar, hosted and moderated by William Sauvé, MD, Chief Medical Officer of Osmind.

🗓️Mark your calendar: Tuesday, August 25 at 10:00 pm PT / 1 pm ET

Can’t make it live? Register anyway and we’ll share the recording
(link in comments)

08/04/2026

Get dedicated COMP360 resources. Prepare your practice for psychedelics.

We've built a growing vault of psychedelic practice resources inside the Psychiatry Collective, including guides to staffing your team, building infrastructure, timing your rollout, and a checklist of what comes next.

Interested in adding these treatments as they become available?

Get Access - link in comments →

07/29/2026

The FDA approved Vi**ra in 1998. It took another 17 years to approve the first drug for low sexual desire in premenopausal women, and Anita Clayton, MD, spent much of that time challenging how medicine studied women’s sexual health.

When fluoxetine’s label reported sexual dysfunction in just 1.9% of patients, Clayton was seeing closer to 20% in her Navy clinic. So she built the measurement tool that helped prove the gap.

Three decades later, the CSFQ is used in drug trials across psychiatry, cardiology, and neurology. Dr. Clayton now chairs psychiatry at UVA and is one of the researchers most responsible for changing how medicine measures antidepressant sexual dysfunction.

On the new episode of Psychiatry Tomorrow, William Sauvé, MD and Brittany Albright MD, MPH, DABOM sit down with her for a career-spanning conversation about:

• The three kinds of sexual dysfunction clinicians need to distinguish: disease-related, treatment-emergent, and relationship-based
• The FDA double standard she fought during Addyi’s approval, a story documented in "The Pink Pill"
• The treatments she’s studying now, including faster-acting options for postpartum depression and an antidepressant without sexual side effects

“Have you ever talked to a woman and asked her if she’s had a successful sexual event?”

The FDA’s original benchmark for Addyi was borrowed from Vi**ra trials.

Clayton found the comparison absurd, and helped push regulators to rethink it.

Listen to or read the full conversation. Search “Psychiatry Tomorrow” on your favorite podcast player, or find the link below.

Anita Clayton, MD, built the scale for measuring antidepressant sexual dysfunction. She made psychiatry pay attention to women's sexcual health, and was featured in the documentary "The Little Pink Pill." Learn to tell disease, medication, and relationship causes apart.